关注
Brendon L Neuen
Brendon L Neuen
The George Institute for Global Health, Royal North Shore Hospital
在 georgeinstitute.org.au 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Chronic kidney disease
K Kalantar-Zadeh, TH Jafar, D Nitsch, BL Neuen, V Perkovic
The Lancet, 2021
7992021
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ...
The lancet Diabetes & endocrinology 7 (11), 845-854, 2019
7822019
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta‐analysis
T Toyama, BL Neuen, M Jun, T Ohkuma, B Neal, MJ Jardine, ...
Diabetes, Obesity and Metabolism 21 (5), 1237-1250, 2019
2812019
Chronic kidney disease and the global NCDs agenda
BL Neuen, SJ Chadban, AR Demaio, DW Johnson, V Perkovic
BMJ global health 2 (2), e000380, 2017
2682017
Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS Program
BL Neuen, T Ohkuma, B Neal, DR Matthews, D De Zeeuw, KW Mahaffey, ...
Circulation 138 (15), 1537-1550, 2018
2572018
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
TNDPHRSG the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists Consortium
The Lancet 400 (10365), 1788-1801, 2022
2282022
Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis
C Arnott, Q Li, A Kang, BL Neuen, S Bompoint, CSP Lam, A Rodgers, ...
Journal of the American Heart Association 9 (3), e014908, 2020
2222020
Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey
AK Bello, A Levin, M Lunney, MA Osman, F Ye, GE Ashuntantang, ...
bmj 367, 2019
2152019
Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials
BL Neuen, M Oshima, R Agarwal, C Arnott, DZ Cherney, R Edwards, ...
Circulation 145 (19), 1460-1470, 2022
1492022
Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis
JT Ha, BL Neuen, LP Cheng, M Jun, T Toyama, MP Gallagher, MJ Jardine, ...
Annals of internal medicine 171 (3), 181-189, 2019
1442019
Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a posthoc analysis from the CREDENCE trial
M Oshima, BL Neuen, JW Li, V Perkovic, DM Charytan, D de Zeeuw, ...
Journal of the American Society of Nephrology 31 (12), 2925-2936, 2020
1192020
Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program
BL Neuen, T Ohkuma, B Neal, DR Matthews, D De Zeeuw, KW Mahaffey, ...
Journal of the American Society of Nephrology 30 (11), 2229-2242, 2019
1182019
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
BL Neuen, M Oshima, V Perkovic, R Agarwal, C Arnott, G Bakris, ...
European heart journal 42 (48), 4891-4901, 2021
1012021
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
M Oshima, BL Neuen, MJ Jardine, G Bakris, R Edwards, A Levin, ...
The Lancet Diabetes & Endocrinology 8 (11), 903-914, 2020
902020
Peritoneal dialysis use and practice patterns: an international survey study
Y Cho, AK Bello, A Levin, M Lunney, MA Osman, F Ye, GE Ashuntantang, ...
American Journal of Kidney Diseases 77 (3), 315-325, 2021
882021
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
JW Li, B Neal, V Perkovic, D de Zeeuw, BL Neuen, C Arnott, R Simpson, ...
Kidney international 98 (3), 769-777, 2020
872020
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease
Z Zhou, MJ Jardine, Q Li, BL Neuen, CP Cannon, D De Zeeuw, ...
Stroke, 2021
792021
Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial
N Ye, MJ Jardine, M Oshima, C Hockham, HJL Heerspink, R Agarwal, ...
Circulation 143 (18), 1735-1749, 2021
692021
Predictors of patency after balloon angioplasty in hemodialysis fistulas: a systematic review
BL Neuen, R Gunnarsson, AC Webster, RA Baer, J Golledge, ML Mantha
Journal of Vascular and Interventional Radiology 25 (6), 917-924, 2014
632014
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
T Sen, J Li, BL Neuen, B Neal, C Arnott, CR Parikh, SG Coca, V Perkovic, ...
Diabetologia 64 (10), 2147-2158, 2021
532021
系统目前无法执行此操作,请稍后再试。
文章 1–20